Longitudinal associations of chemotherapy-induced peripheral neuropathy with psychological distress and health-related quality of life in colorectal cancer survivors: a prospective cohort study

Le résumé fourni par la source

PURPOSE: Colorectal cancer (CRC) survivors receiving oxaliplatin-based chemotherapy frequently develop chemotherapy-induced peripheral neuropathy (CIPN). This study investigated the impact of CIPN symptoms on psychological distress and health-related quality of life (HRQoL) among oxaliplatin-treated CRC survivors up to 5 years post-treatment. METHODS: 124 CRC patients treated with oxaliplatin-based chemotherapy participating in a prospective cohort study were included in the longitudinal analyses. CIPN symptoms were measured at diagnosis (pre-treatment) and at 6 weeks and 6, 12, 24, and 60 months post-treatment using the European Organization for Research and Treatment of Cancer Quality of Life Questionnaire-CIPN20 (EORTC QLQ-CIPN20). Psychological distress, including anxiety and depressive symptoms, and HRQoL were measured at all post-treatment time points using the Hospital Anxiety and Depression Scale (HADS) and the EORTC QLQ-Core 30 (EORTC QLQ-C30), respectively. Confounder-adjusted longitudinal associations of CIPN symptoms with psychological distress and HRQoL were analysed with linear mixed regression models. RESULTS: CIPN symptoms in oxaliplatin-treated CRC patients were highest at 6 weeks post-treatment, thereafter gradually decreasing over time. More severe CIPN symptoms were longitudinally associated with more psychological distress (HADS), including both higher anxiety and depressive symptoms, and with worse global health/QoL and physical and social functioning and more fatigue (EORTC QLQ-C30). CONCLUSION: CIPN symptoms, persisting over time among oxaliplatin-treated CRC survivors, were longitudinally associated with more psychological distress and lower HRQoL up to 5 years after chemotherapy treatment. IMPLICATIONS FOR CANCER SURVIVORS: CIPN symptoms following oxaliplatin-based chemotherapy have a long-lasting impact on CRC survivors. Research on interventions aimed at mitigating CIPN symptoms is warranted.

Ce résumé expose les affirmations des auteurs. BNTIC ne l’interprète pas comme une validation indépendante des résultats.